Recent 8-K filings for GKOS

• April 29, 2026, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 7.01item 9.01 ◈ Earnings Releases

  Glaukos Q1 record sales $150.6M (+41% YoY); raises FY2026 guidance to $620-635M

  Record net sales $150.6M (+41% YoY, +39% constant currency).

• February 17, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 7.01item 9.01

  Glaukos Q4 record sales $143.1M (+36% YoY); reaffirms FY2026 guidance $600-620M

  Q4 net sales $143.1M (record), +36% YoY; full year $507.4M, +32% YoY.

• January 13, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 7.01item 9.01

  Glaukos reports preliminary Q4 2025 net sales ~$143M (+36% YoY); reaffirms FY2026 guidance $600-620M

  Q4 2025 net sales ~$143M (+36% YoY); FY2025 net sales ~$507M (+32% YoY).

• October 29, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 7.01item 9.01

  Glaukos Q3 revenue $133.5M (+38% YoY); raises 2025 guide, introduces 2026 outlook

  Record net sales $133.5M, up 38% YoY; U.S. Glaucoma sales $80.8M (+57% YoY).

• July 30, 2025, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 7.01item 9.01

  Glaukos Q2 record net sales $124.1M (+30% YoY); raises FY 2025 guidance to $480-486M

  Record net sales $124.1M, up 30% YoY; glaucoma sales $103.5M (+36%), U.S. glaucoma $72.3M (+45%).

• April 30, 2025, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 7.01item 9.01

  Glaukos Q1 net sales record $106.7M (+25% YoY); net loss narrows to $0.32/sh from $0.82

  Record Q1 net sales $106.7M, up 25% reported and 26% constant currency vs $85.6M last year.

• February 20, 2025, 6:59 PM ET earnings materiality 0.70 positive item 2.02item 7.01item 9.01

  Glaukos Q4 record net sales $105.5M, +28% YoY; guides FY2025 $475-485M

  Q4 net sales record $105.5M, +28% YoY; glaucoma segment $84.1M (+39%).

• December 3, 2024, 6:59 PM ET other material materiality 0.60 neutral item 1.01item 9.01

  Glaukos partially unwinds capped calls on 2027 convertible notes; receives cash based on VWAP

  Entered into unwind agreements for 50% of capped call transactions associated with $287.5M 2.75% convertible notes due 2027.

• November 4, 2024, 6:59 PM ET earnings materiality 0.70 positive item 2.02item 7.01item 9.01

  Glaukos Q3 revenue $96.7M (+24% YoY), raises 2024 guidance to $377-379M

  Record Q3 net sales of $96.7M (+24% YoY); glaucoma segment $76.0M (+30%), corneal health $20.6M (+5%).

• July 31, 2024, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 7.01item 9.01

  Glaukos reports record Q2 sales $95.7M (+19% YoY), raises FY2024 guidance

  Record net sales of $95.7M, up 19% reported / 20% constant currency YoY.

• June 28, 2024, 7:59 PM ET other material materiality 0.75 neutral item 3.02item 8.01

  Glaukos exchanges $230M of 2.75% convertible notes for 4.25M shares of common stock

  Exchanged $230M principal of 2.75% Convertible Senior Notes due 2027 for 4,253,423 common shares and cash.

• June 14, 2024, 7:59 PM ET other material materiality 0.85 neutral item 3.02item 8.01item 9.01

  Glaukos exchanges $230M of 2.75% Convertible Notes due 2027 for common stock

  Glaukos entered agreements to repurchase $230M of its 2.75% Convertible Senior Notes due 2027.

• May 1, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 7.01item 9.01 ◈ Earnings Releases

  Record Q1 net sales of $85.6M (+16% YoY); raised 2024 guidance to $357-$365M

  Glaucoma segment sales $67.2M (+20% YoY); Corneal Health $18.4M (+4% YoY).

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.53 · Most common event earnings

11 positive 0 negative 17 neutral

source · GKOS on sec.gov